Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Infection during biologic and immunosuppressive treatment
Essential points for quick revision.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Serious infection with blunted inflammation
Shock, hypoxaemia, meningism, encephalopathy, severe abdominal pain, disseminated vesicles or rapidly progressive focal disease can occur with little fever, leukocytosis or CRP response during targeted immune suppression.
Action: Use ABCDE, obtain cultures and focused samples without harmful delay, start syndrome-appropriate empirical treatment and involve microbiology or infection specialists. Withhold the implicated biologic or targeted drug in serious infection after urgent specialist communication, but never abruptly stop chronic corticosteroids.
Synopsis
Infer infection risk from the targeted immune defect, recognise masked and opportunistic presentations, treat serious infection promptly and coordinate safe interruption, prophylaxis and restart of immunosuppression.
Name every immune-modifying medicine, last dose, cumulative corticosteroid exposure and combination therapy; risk follows mechanism and intensity rather than the word biologic alone.
TNF inhibition impairs granuloma maintenance and raises tuberculosis and other intracellular-pathogen risk; monoclonal anti-TNF antibodies generally carry greater TB-reactivation concern than etanercept.
B-cell depletion can cause hepatitis B reactivation, hypogammaglobulinaemia, impaired vaccine responses and prolonged viral susceptibility months after the last infusion.
Key red flags
Hypotension, confusion, new oxygen need, oliguria or rising lactate is serious infection regardless of a normal temperature or inflammatory marker.
Masked bacterial sepsis
Fatigue, confusion, tachypnoea, hypotension or focal pain can precede fever and CRP elevation during corticosteroid or IL-6-pathway suppression.
Investigation priorities
01
Treatment and immune-defect inventoryFirst step
Identify the mechanistic infection pattern, duration of residual effect and medicines that require temporary interruption or interaction review.
02
First-line syndrome samplingFirst line
Diagnose common bacterial, viral or fungal infection and secure susceptibility data before empirical treatment reduces yield.
Management branches
ACUTE ILLNESSTreat the clinical syndrome
A patient receiving an immune-modifying medicine develops possible serious infection or sepsis physiology.
Perform ABCDE, obtain blood and focus cultures immediately and start the local syndrome-specific empirical regimen when severe infection is possible.
Identify the immune mechanism and add tests or cover only for credible gaps, such as tuberculosis with anti-TNF, VZV with JAK inhibition or meningococcus with complement blockade.
Key medicines
Syndrome-directed empirical antimicrobialsUse the current local severe-infection regimen for the anatomical source at full loading dose, modified immediately for immune mechanism, allergy, organ function, prior organisms and resistance exposure.
Co-trimoxazole prophylaxisA commonly used adult regimen is 960 mg orally three times weekly or 480 mg once daily when specialist assessment identifies material Pneumocystis risk.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.